In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.
Overview of Antoquinone
Antroquinonol (Hocena) is being developed for the treatment of relapsed acute myeloid leukemia, acute myeloid leukemia, non-squamous non-small cell lung cancer, metastatic pancreatic cancer, chronic hepatitis B, hepatocellular carcinoma, and non-familial hypercholesterolemia , mixed hyperlipidemia and Alzheimer’s disease. The drug candidate is an orally administered small molecule. It is a new chemical entity (NCE). The drug candidate is a ubiquinone derivative. It is a cyclohexenone compound purified from Antrodia camphorata extract. This drug candidate targets farnesyltransferase and downregulates the PI3K and mTOR signaling pathways. It is also developing drugs to treat atopic dermatitis. It is also being developed to prevent coronavirus disease 2019 (COVID-19) with pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Overview of Gordon Biotechnology
Golden Biotechnology (Golden Biotech) is a drug discovery and dietary supplement manufacturing company. The company develops and markets pharmaceuticals and herbal supplements used to prevent and treat a variety of cancer diseases. It discovers new drugs to treat cardiometabolic syndrome, autoimmune diseases, neurodegenerative diseases and infectious diseases through its screening platform. Golden Biotech also offers products under the liverty, zsaino, rasle and umooze brands. It has centers completing Covid-19 clinical trials in the United States, Peru and Argentina. The company’s products are sold to China, Taiwan, the United States, Malaysia and Japan. Golden Biotech is headquartered in New Taipei, Taiwan.
For complete information on Antroquinonol drug-specific PTSR and LoA scores, purchase the report here.
Desde
The gold standard in business intelligence.
GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.
GlobalData, a leading provider of industry intelligence, provided the underlying data, research and analysis used to write this article.
GlobalData’s Likelihood of Approval Analysis tool dynamically assesses and predicts the likelihood of a drug advancing to the next phase of clinical development (PTSR), as well as the likelihood of drug approval (LoA). This is based on a combination of machine learning and proprietary algorithms used to process data points from various databases in GlobalData’s Pharmaceutical Intelligence Center.